BETHESDA, Md., May 27 /PRNewswire/ — A new public-private
partnership between AstraZeneca and NIH’s National Institute of
Diabetes and Digestive and Kidney Diseases (NIDDK) will focus on
supporting the work of the Drug-Induced Liver Injury Network
(DILIN). DILIN is a group working to bring together essential
scientific and financial resources to better understand drug-induce
liver injury as well as effective screening, diagnostic and
treatment options.
Drug-induced liver injury, whether caused by prescription or
non-prescription medication, is the most common cause of acute
liver failure in the United
States. It is the major reason for non-approval, withdrawal
and limiting the prescribing of medications by the Food and Drug
Administration.
Under the terms of the partnership, AstraZeneca will join other
companies to provide funding for the project. AstraZeneca
will also have a seat on a DILIN scientific board, a group convened
by FNIH that includes representatives of all the partners in this
endeavor, to provide expertise and input on scientific and
technical matters. No details of the financial support were
disclosed.
“AstraZeneca is keen to support this important project to help
the industry and the medical community better understand and
mitigate the risks of liver damage associated with the use of some
medicines,” said Joachim Forsgren,
VP and Global Head of Patient Safety at AstraZeneca. “The
safety of patients who need drugs to treat many different kinds of
conditions and illnesses is paramount in both developing new
medicines and safely and effectively using products currently on
the market. We want to play our part in furthering this critical
work, which will provide valuable insight t
‘/>”/>
